Metastatic Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Kevin Kalinsky

In this episode of the Oncology Brothers podcast we navigated the rapidly evolving treatment landscape of Metastatic Hormone Receptor-Positive Breast Cancer. We were joined by Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University, to discuss the implications of new targeted therapies, optimal sequencing strategies, and practical toxicity management.   The discussion covered: The critical role of NGS testing (tissue vs. liquid biopsy) in identifying PIK3CA, ESR1, AKT1 and PTEN alterations. Frontline management of high-risk, endocrine-resistant disease with the inavolisib triplet (INAVO120) and its overall survival benefit. Choosing between CDK4/6 inhibitors (abemaciclib vs. ribociclib) in de novo metastatic disease. Post-CDK4/6 inhibitors on progression we covered, the use of oral SERDs (imlunestrant) and AKT inhibitors (capivasertib). The "ADC explosion", sequencing T-DXd (DESTINY-Breast06), sacituzumab govitecan (TROPiCS-02), and datopotamab deruxtecan (TROPION-Breast01). Clinical pearls for managing toxicities: stomatitis, hyperglycemia, rash, neutropenia, and ILD. Join us as we break down the latest data and provide actionable insights for the practicing oncologist.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/    Don't forget to subscribe for more episodes in our breast cancer algorithm series! #MetastaticBreastCancer, #HRPositive, #ADCsequencing, #PIK3CA-AKT, #OncologyPodcast, #OncologyBrothers